Tag - ACHV

Executive Moves

Achieve appoints Dr. Mark Rubenstein as CMO

Achieve Life Sciences (NASDAQ: ACHV) has announced the promotion of Mark Rubenstein, MD, from interim chief medical officer (CMO) to CMO. Dr. Rubinstein brings more than two decades of experience in clinical medicine...

January 12, 2026

Markets

Ladenburg cuts Achieve Life Sciences PT to $50 from $80

Ladenburg Thalmann lowered its price target for Achieve Life Sciences (NASDAQ:ACHV) to $50 from $80, but retained a “buy” rating, citing dilution as well as a reduction in the projected price level of future financings...

November 10, 2021

Feature

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

Achieve Life Sciences (NASDAQ:ACHV) began a pivotal trial in the fourth quarter of 2020 to evaluate cytisinicline, which is derived from the seeds of the laburnum tree, as a potential new treatment for smoking cessation...

February 16, 2021

Tag - ACHV

Achieve appoints Dr. Mark Rubenstein as CMO

Ladenburg cuts Achieve Life Sciences PT to $50 from $80

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

Subscribe